Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: An update

Kimme Hyrich, et al.

Research output: Contribution to journalArticlepeer-review

24 Downloads (Pure)


Background. Targeting IL-6 has become a major therapeutic strategy in treatment of immune-mediated inflammatory disease. Interference with the IL-6 pathway can be directed at the specific receptor using anti-IL-6Rα antibodies, or by inhibiting the IL-6 cytokine directly. This is an update of a previous consensus document aiming to inform on the interference with the IL-6 pathway based on evidence and expert opinion.
Methods. A systematic literature search was performed that focused on IL6-pathway inhibitors in rheumatoid arthritis and other diseases. Evidence was put in context by a large group of international experts and patients in a subsequent consensus process. All were involved in formulating the consensus statements, and in the preparation of this document.
Results. The consensus covers relevant aspects of dosing and populations for different indications of IL-6 pathway inhibitors that are approved across the world, including rheumatoid arthritis, polyarticular-course and systemic juvenile idiopathic arthritis, giant cell arteritis, Takayasu disease, adult-onset Still’s disease, Castleman’s disease, CAR-T-cell induced cytokine release syndrome, neuromyelitis optica spectrum disorder. Furthermore they cover aspects of pre-treatment screening, safety, contraindications, and monitoring.
Conclusions. The document provides a comprehensive consensus on IL-6 pathway inhibitors to inform patients, administrators and payers.
Original languageEnglish
JournalAnnals of the rheumatic diseases
Publication statusAccepted/In press - 18 Jul 2022


Dive into the research topics of 'Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: An update'. Together they form a unique fingerprint.

Cite this